Talking TPD with Ben Cross, CTO and Head of Platform at PhoreMost
Like this interview? See more like it below:
- Drugging the Undruggable: Targeted Protein Degraders
- Challenges and Opportunities in Targeted Protein Degraders : Current and Future Strategies
- Interview with Yusuke Tominari, Co founder and CEO of Fimecs
Join and network with over 450 industry discovery biology and chemistry leaders at the renowned Drug Discovery Summit in Basel, where they address critical strategies in target identification, validation
and HIT optimisation of small and large molecule drugs.
Speaker Biographies
Benedict Cross is CTO at PhoreMost, a next-generation target and drug discovery company. He joined in 2019 to lead the evolution and development of the SITESEEKER® screening platform which uses PROTEINi to discover new drugs. Before PhoreMost, Ben founded and led the CRISPR-based functional genomic screening department at the leading UK gene editing biotech, Horizon Discovery. He is a geneticist and biotechnologist, with over ten years of professional research and management experience and has a background in proteostasis and chemical genetic screening